Bellecapital International Ltd. grew its position in shares of Eli Lilly And Co (NYSE:LLY) by 4.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,369 shares of the company’s stock after purchasing an additional 250 shares during the quarter. Bellecapital International Ltd.’s holdings in Eli Lilly And Co were worth $595,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Trust Department MB Financial Bank N A grew its holdings in shares of Eli Lilly And Co by 54.7% in the first quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock worth $30,000 after acquiring an additional 82 shares during the period. WP Advisors LLC bought a new stake in shares of Eli Lilly And Co in the first quarter worth $38,000. Meridian Wealth Management LLC purchased a new position in Eli Lilly And Co during the first quarter valued at $38,000. Ellis Investment Partners LLC purchased a new position in Eli Lilly And Co during the first quarter valued at $39,000. Finally, Larson Financial Group LLC lifted its position in Eli Lilly And Co by 80.6% during the first quarter. Larson Financial Group LLC now owns 448 shares of the company’s stock valued at $58,000 after purchasing an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 79.48% of the company’s stock.
In other Eli Lilly And Co news, CFO Joshua L. Smiley acquired 426 shares of the firm’s stock in a transaction dated Wednesday, June 5th. The stock was purchased at an average price of $118.03 per share, for a total transaction of $50,280.78. Following the acquisition, the chief financial officer now owns 30,410 shares in the company, valued at approximately $3,589,292.30. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Michael J. Harrington sold 16,000 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $116.72, for a total value of $1,867,520.00. Following the sale, the vice president now owns 110,300 shares of the company’s stock, valued at approximately $12,874,216. The disclosure for this sale can be found here. 0.11% of the stock is owned by corporate insiders.
Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.45 by $0.05. The firm had revenue of $5.64 billion during the quarter, compared to analyst estimates of $5.59 billion. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. Eli Lilly And Co’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.48 earnings per share. Analysts forecast that Eli Lilly And Co will post 5.72 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a dividend of $0.645 per share. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $2.58 dividend on an annualized basis and a yield of 2.34%. Eli Lilly And Co’s dividend payout ratio is currently 46.49%.
Several research firms recently weighed in on LLY. Goldman Sachs Group began coverage on Eli Lilly And Co in a research report on Tuesday, May 28th. They set a “buy” rating and a $135.00 target price on the stock. Edward Jones upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price objective on the stock in a research report on Tuesday, April 23rd. BMO Capital Markets boosted their price objective on Eli Lilly And Co from $130.00 to $133.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Zacks Investment Research downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, May 21st. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $143.00 price objective on shares of Eli Lilly And Co in a research report on Tuesday, April 30th. Nine investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Eli Lilly And Co presently has an average rating of “Buy” and an average target price of $123.49.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: Limitations of the P/E Growth ratio
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.